- Name Helen McCarthy
- Institute Queen's University Belfast
Tool name: pCMV-iNOS Vector
Alternate names: Nitric Oxide Synthase
Tool type: Vector
Tool sub-type: pcDNA 3.1
Description: pCMV-iNOS Plasmid is a human nitric oxide synthase (iNOS) transgene driven by a constitutively active CMV (cytomegalovirus) promoter. Originally developed as an anti-cancer therapeutic with a view to a gene therapy strategies that address hormone refractory prostate cancer (HRPC). Studies in the literature have demonstrated that this plasmid is capable of delaying tumour growth (Adams et al., 2009). The plasmid serves as a useful tool in cardiovascular studies or any physiology associated with vasodilation.
Research area: Cancer; Metabolism; Neurobiology
Bacterial resistance: Kanamycin
- For Research Use Only
- • Adams et al. 2009. J Gene Med. 11(2):160-8. PMID: 19062185.
- • Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells.
- • Coulter et al. 2008. Gene Ther. 15(7):495-503. PMID: 18256696.
- • The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.
- • McCarthy et al. 2007. J Gene Med. 9(6):511-20. PMID: 17471586.
- • Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
- • McCarthy et al. 2007. Gene Ther. 14(3):246-55. PMID: 17006546.
- • p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.
- • Worthington et al. 2002. Gene Ther. 9(4):263-9. PMID: 11896465.
- • Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy.